Consistently, blocking IKKβ or mTOR signaling with Bay 11-7082 or rapamycin, respectively, inhibits the liver cancer cell growth and VEGF-A production, suggesting that inhibitors of IKKβ or mTOR signaling may be useful as new therapeutics for the treatment of HBV-associated HCC. This evidence concerns the gene VEGFA and hepatocellular carcinoma.